Ryght AI, a platform provider for life sciences and clinical research companies, has announced the public availability of its enterprise-grade generative AI platform, Ryght Preview. This move marks a significant step forward in streamlining clinical research operations, enhancing efficiency, and accelerating the development process. With Ryght Preview, knowledge workers can experience the benefits of secure, industry-specific, and enterprise-level GenAI technology.
What Happened
Ryght AI has been working on its generative AI platform for some time now, with a focus on addressing the challenges faced by life sciences companies in clinical research. The company's goal is to empower these professionals to get the insights they need swiftly and securely. To achieve this, Ryght AI is building a SaaS platform that offers industry-specific AI copilots and custom-built solutions for professionals and organizations.
The partnership with Hugging Face has played a crucial role in expediting the development of Ryght's generative AI platform. The rapidly evolving landscape of AI has the potential to revolutionize industries, and Hugging Face's highly performant and enterprise-ready Text Generation Inference (TGI) and Text Embeddings Inference (TEI) services are game changers in their own right.
Background and Context
The clinical trial process is becoming increasingly complex, leading to major delays. Manual site selection can add weeks or months to each study, creating significant bottlenecks that slow down the entire development process. Ryght AI addresses these challenges through its AI Site Twin platform, which creates dynamic digital replicas of clinical research sites.
The company's technology is designed to optimize workflows, boost operational efficiency, and unlock new potential for the healthcare and life sciences industries. By granting access to its platform, Ryght facilitates smoother operations and communication across critical entities. Utilizing a wealth of clinical data and an ever-growing array of copilots, Ryght enhances clinical operations efficiency, delivering actionable insights and informed decision-making.
Why It Matters
The investment in Ryght AI by Accenture Ventures is a significant development for the life sciences industry. This partnership will combine Accenture's deep industry, technology, and data-engineering expertise with Ryght AI's advanced domain-specific agentic AI platform to help life sciences companies accelerate the three most crucial steps in drug development.
The use of generative and agentic AI is transforming the foundation of clinical research. With this investment, life sciences companies will be able to fully leverage operational and scientific data and bring life-changing therapies to market faster, more efficiently, and with greater precision.
What Comes Next
Ryght Preview is available to life sciences knowledge workers as a free, secure platform with frictionless sign-up. The company's copilot library consists of a diverse collection of tools to accelerate information retrieval, synthesis, and structuring of complex and unstructured data, and document builders.
The full enterprise version of Ryght will offer additional features and capabilities. Custom-built solutions can be added to the platform to reduce friction and optimize operations across all aspects of the clinical research continuum and beyond.
Key Facts
- Ryght AI has announced the public availability of its enterprise-grade generative AI platform, Ryght Preview.
- The platform is designed to streamline clinical research operations, enhance efficiency, and accelerate the development process.
- Ryght AI's partnership with Hugging Face has played a crucial role in expediting the development of its generative AI platform.
- The company's technology addresses challenges faced by life sciences companies in clinical research, including manual site selection and patient enrollment.
- Accenture Ventures has invested in Ryght AI to help life sciences companies transform clinical research with agentic AI.
Ryght Preview is a significant step forward for the life sciences industry, offering a secure and user-friendly platform designed to meet the diverse needs of professionals looking to accelerate drug development. With its focus on streamlining interactions among research sites, Clinical Research Organizations (CROs), and clinical trial sponsors, Ryght AI is poised to make a lasting impact in the industry.
